Effect of beta-blocker treatment in dilated cardiomyopathy with bradyarrhythmias.
This study was performed to evaluate whether beta-blocker therapy was effective in patients with nonischemic dilated cardiomyopathy (DCM) and bradyarrhythmias supported by pacemaker implantation. Beta-blocker therapy is useful for some patients with DCM, especially those with rapid heart rate or residual nonfibrotic myocardium in the left ventricle, but no data exist on whether beta-blocker therapy is useful in patients with DCM and bradyarrhythmias. The effectiveness of beta-blocker therapy was prospectively evaluated in patients with DCM and bradyarrhythmias supported by pacemaker implantation and compared with those without these arrhythmias. Beta-blocker therapy was started in 63 patients (45 men, 18 women, aged 11-83 years) with DCM, in whom 7 had bradyarrhythmias and 56 did not. These bradyarrhythmias were atrioventricular block, sick sinus syndrome and atrial fibrillation with slow heart rate. Of the 56 patients without bradyarrhythmias, 42 (75%) (group 1) responded to beta-blocker therapy, but 5 of the 7 with bradyarrhythmias (71%) (group 2) also responded. Left ventricular end-diastolic dimension was reduced (6.5 +/- 0.6 cm to 5.6 +/- 0.5 cm; p < 0.0001 in group 1; 6.6 +/- 0.8 cm to 5.5 +/- 0.2 cm; p < 0.02 in group 2) and left ventricular fractional shortening was improved (13 +/- 4% to 27 +/- 7%; p < 0.0001 in group 1; 12 +/- 4% to 29 +/- 10%; p < 0.05, in group 2) to the same degree in both groups. These results indicate that beta-blocker therapy for DCM is effective not only in patients without bradyarrhythmias but also in those with bradyarrhythmias supported with pacemaker implantation.